SMMT
NASDAQ HealthcareSummit Therapeutics Inc. - Common Stock
Biotechnology
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
๐ Market Data
| Price | $16.11 |
|---|---|
| Volume | 18,026,280 |
| Market Cap | 12.51B |
| RSI (14-Day) | 39.1 |
| 200-Day MA | $19.71 |
| 50-Day MA | $18.36 |
| 52-Week High | $30.98 |
| 52-Week Low | $13.83 |
| Forward P/E | -13.67 |
| Price / Book | 18.96 |
๐ฏ Investment Strategy Scores
SMMT scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (90/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Over-Hyped (15/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find SMMT in your text
Paste any article, transcript, or post โ the tool will extract SMMT and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.